Ptc Therapeutics (PTCT) Profit After Tax (2012 - 2026)

Ptc Therapeutics' Profit After Tax history runs 15 years deep, the most recent figure standing at $83.5 million for Q2 2026.

• In Q2 2026, Profit After Tax rose 228.75% year-over-year to $83.5 million; the TTM figure through Jun 2026 stood at -$38.4 million (down 106.1% YoY), while the FY2025 annual figure was $682.6 million, up 287.9% from the prior year.
• Profit After Tax for Q2 2026 stood at $83.5 million, up from -$2.8 million in the prior quarter.
• The five-year high for Profit After Tax was $866.6 million in Q1 2025, with the low at -$198.9 million in Q2 2023.
• The 5-year median for Profit After Tax is -$108.0 million (2022), against an average of -$43.6 million.
• Peak annual rise in Profit After Tax reached 1046.28% in 2025, while the deepest fall reached 104.85% in 2025.
• Ptc Therapeutics' Profit After Tax stood at -$170.9 million in 2022, then increased by 8.83% to -$155.8 million in 2023, then surged by 57.71% to -$65.9 million in 2024, then slumped by 104.85% to -$135.0 million in 2025, then surged by 161.86% to $83.5 million in 2026.
• Business Quant data shows PTCT's Profit After Tax at $83.5 million in Q2 2026, -$2.8 million in Q1 2026, and -$135.0 million in Q4 2025.